METHODS AND COMPOUNDS FOR TREATMENT OF LYMPHOCYTE-RELATED DISEASES AND CONDITIONS
Methods for treatment of lymphocyte-related diseases and conditions, such as cancer and automimmune diseases, are provided. The methods comprise administration of an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises, inter alia, at least one intersubunit linkage having the following structure: wherein R1, L1, X, Y and Z are as defined herein.
This application is continuation application of U.S. application Ser. No. 15/579,497, filed Dec. 4, 2017, which is a 35 U.S.C. § 371 filing of International Patent Application No. PCT/US2016/035671, filed Jun. 3, 2016, which application claims priority to U.S. Provisional Application Ser. No. 62/171,102, filed Jun. 4, 2015, which is incorporated herein by reference in its entirety.
STATEMENT REGARDING SEQUENCE LISTINGThe Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is SPT_8125USCON_SEQUENCE_LISTING.txt. The text file is 8.2 KB, was created on Apr. 28, 2021, and is being submitted electronically via EFS-Web.
BACKGROUND Technical FieldThe present invention is generally related to oligonucleotide compounds (oligomers) and methods for their use as antisense compounds, and more particularly to methods for use of the oligonucleotide compounds for treatment of lymphocyte-related diseases and conditions.
Description of the Related ArtAntisense oligonucleotides are useful tools for inhibiting gene expression and are the subject of ongoing investigation as therapeutic agents. Lymphoid cells, including T lymphocytes and B lymphocytes, are important target cells for therapeutic antisense strategies. Lymphocytes are white blood cells that largely mediate the adaptive immune response. Lymphocytes include natural killer (NK) cells, T cells, and B cells. T cells and B cells are involved in cell-mediated immunity and humoral immunity, respectively, through their recognition of “non-self” antigens via cell surface receptors. The antigen receptor of B cells is a membrane bound form of the immunoglobulin that they will secret upon activation. Upon activation (i.e., binding of the antigen to the B cell receptor), the B cell differentiates into plasma cells that secrete immunoglobulins. The antigen receptor of T cells is a membrane bound heterodimeric receptor associated with the proteins of the CD3 complex. Most T lymphocytes have α:β heterodimeric receptors, but some T cells have γ:δ receptors.
Two simultaneous signals are required to activate a T lymphocyte. One signal is provided by a peptide bound to an MHC protein on the surface of an antigen presenting cell (APC). The peptide-MHC complex signals through the T cell receptor and its associated proteins. The second signal is provided by co-stimulatory molecules on the APC (e.g., CD80 and CD86), which are recognized by a co-stimulatory receptor (e.g., CD28) on the T cell surface. The combination of the two signals stimulates the T cell to proliferate and begin to differentiate into an effector T cell (e.g., cytotoxic CD8+ T cell, TH1 cell, TH2 cell). Cytotoxic T cells kill infected target cells through the release of lytic granules into antigen-bearing target cells. TH1 cells activate microbicidal properties of infected macrophages and induce B cells to produce opsonizing IgG antibodies. TH2 cells activate naïve B cells to secrete IgM and induce production of other antibody isotypes. Regulatory T cells (Tregs) are a subpopulation of T cells involved in maintaining tolerance to self-antigens. Treg function or dysfunction may be an important factor in numerous pathological settings, including autoimmunity, allergy, infection, tumor immunity, organ transplantation, and fetal-maternal tolerance.
T cells are frequent therapeutic targets for inhibiting chronic inflammation or cytotoxicity associated with autoimmune diseases. For example, defective apoptosis of autoreactive T cells is implicated in the pathogenesis of multiple sclerosis. Antisense oligonucleotides for an X-linked inhibitor of apoptosis (XIAP) was found to increase susceptibility of T cells to activation-induced apoptosis in vitro and alleviated experimental autoimmune encephalomyelitis and prevented relapses in mice (Zehntner et al., 2007, J. Immunol. 179:7553-7560). In another example, migration of T lymphocytes into the intestinal mucosa plays a crucial role in the pathogenesis of inflammatory bowel disease (IBD) (e.g., Crohn's disease or ulcerative colitis). Antisense inhibition of Smad7, an inhibitor of TGF-β1 signaling that is overexpressed in inflammatory bowel disease mucosa and purified mucosal T cells, enabled IBD cell samples to respond to TGF-β1 and downregulated proinflammatory cytokines (U.S. Pat. No. 7,700,757; Monteleone et al., 2001, J. Clin. Invest. 108:601-609). In yet another example, synovial T cells may play a crucial role in rheumatoid arthritis induction and promotion, in part due to the production of the proinflammatory cytokine IL-17. Antisense targeting of the transcription factor STAT4 in T lymphocytes suppressed clinical and histopathological signs of collagen-induced arthritis in mice (Hildner et al., 2007, J. Immunol. 178:3427-3436).
The rejection of allogeneic transplants is largely mediated by T cells. Antisense oligonucleotides have been used to inhibit granzyme expression in cytotoxic T lymphocytes, which is associated with tissue destruction in transplantation models (Bailey et al., 2004, Eur. J. Immunol., 27:2302-2309).
HIV-infected T lymphocytes, particularly T helper lymphocytes, or CD4+ T lymphocytes, are targets for antisense strategies against HIV (Lisziewicz et al., 1994, Proc. Natl. Acad. Sci. USA 91:7942-7946; Zhang et al., 1995, Clin. Pharmacol. Ther. 58:44-53; Elmen et al., 2004, FEBS Lett. 578:285-90; Jakobsen et al., 2007, Retrovirology 4:29-41).
Lymphoid cells are also targeted by antisense oligonucleotides for antitumor therapy. By way of example, human T-cell leukemia virus type 1 (HTLV-1) infection is known to cause adult T cell leukemia. Inhibition of syncytium formation in T-cells was observed in vitro with antisense oligonucleotides targeting human T-cell leukemia virus type 1 HTLV-1 tax gene (Maeda et al., 1997, Leukemia 11:42-44). In another example, antisense-mediated inhibition of the protooncogene c-myb inhibited DNA synthesis in T-leukemia cells of most patients (Venturelli et al., 1990 Cancer Res. 50:7371-7375). In yet another example, depletion of regulatory T cells with FOXP3-specific antisense oligonucleotides is being investigated as a way to enhance effector T cell response to tumors (Morse et al., 2012, Cancer Gene Ther. 19:30-37).
Functional efficacy of such antisense oligonucleotide based therapy is limited by insufficient cellular uptake of the oligonucleotide. Exogenous oligonucleotides are primarily taken up through fluid phase endocytosis at oligonucleotide concentrations greater than 1 μM and endocytosis mediated by a receptor-like protein for lower concentrations (Beltinger et al., 1995, J. Clin. Invest. 95:1814-1823). Primary cells are known to incorporate oligonucleotides less efficiently than cell lines (Marti et al., 1992, Antisense Res. Dev. 2:27-39). Furthermore, oligonucleotide uptake is heterogenous among different cell types. Among normal peripheral blood and bone marrow cells, myeloid cells and B cells preferably took up more oligonucleotides than T cells (Zhao et al., 1996, Blood 88:1788-1795). Other studies also showed preferential uptake of oligonucleotides by monocytes and B cells and very low uptake by T cells (Hartmann et al., 1998, J. Pharmacol. Exp. Ther. 285:920-928; Kronenwett et al., 1998, Blood 91:852-862). In fact, Hartmann et al. demonstrated that only 2% of T cells spontaneously incorporated FITC-labeled phosphorothioate oligonucleotides as measured by fluorescence intensity. Mitogen activation may increase oligonucleotide uptake (Kreig et al., 1991, Antisense Res. Dev. 1:161-171; Iversen et al., 1992, Antisense Res. Dev. 2:223-233). Cationic lipids have been used to enhance oligonucleotide uptake into T cells with variable results (Hartmann et al., supra; Kronenwett et al., supra).
T cells are important targets for inhibition by antisense oligonucleotides in the treatment of inflammatory, infectious, and neoplastic diseases. There is a need for alternative compositions and methods for improving uptake of antisense oligonucleotides into T cells. The present disclosure meets this need and further provides other related advantages.
BRIEF SUMMARYMethods described herein are useful for treatment of various lymphocyte (e.g., T-cell) mediated diseases or conditions. While not wishing to be bound to any particular theory, the present applicants believe the presence of certain functional groups, such as guanidinyl, alkylguanidinyl and/or alkylaminyl groups, in antisense oligonucleotides unexpectedly enhances delivery of the antisense oligonucleotides to lymphocytes, such as T-cells. Accordingly, in one embodiment the present disclosure provides a method for treatment of a lymphocyte-related disease or condition, the method comprising administering an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3′-end of one morpholino ring structure to a 5′-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has the following structure (I):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, L1, X, Y and Z are as defined herein.
In certain embodiments, the method is for treatment of a T-cell related disease or condition, the method comprising contacting activated T-cells with the above described oligomer.
These and other aspects of the invention will be apparent upon reference to the following detailed description. To this end, various references are set forth herein which describe in more detail certain background information, procedures, compounds and/or compositions, and are each hereby incorporated by reference in their entirety.
In the figures, identical reference numbers identify similar elements. The sizes and relative positions of elements in the figures are not necessarily drawn to scale and some of these elements are arbitrarily enlarged and positioned to improve figure legibility. Further, the particular shapes of the elements as drawn are not intended to convey any information regarding the actual shape of the particular elements, and have been solely selected for ease of recognition in the figures.
In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments. However, one skilled in the art will understand that the invention may be practiced without these details. In other instances, well-known structures have not been shown or described in detail to avoid unnecessarily obscuring descriptions of the embodiments. Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense, that is, as “including, but not limited to.” Further, headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed invention.
Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. Also, as used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. It should also be noted that the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.
The terms below, as used herein, have the following meanings, unless indicated otherwise:
“Amino” refers to the —NH2 radical.
“Cyano” or “nitrile” refers to the —CN radical.
“Hydroxy” or “hydroxyl” refers to the —OH radical.
“Imino” refers to the ═NH substituent.
“Guanidinyl” refers to the —NHC(═NH)NH2 substituent.
“Nitro” refers to the —NO2 radical.
“Oxo” refers to the ═O substituent.
“Thioxo” refers to the ═S substituent.
“Alkyl” refers to a straight or branched hydrocarbon chain radical which is saturated or unsaturated (i.e., contains one or more double and/or triple bonds), having from one to thirty carbon atoms, and which is attached to the rest of the molecule by a single bond. Alkyls comprising any number of carbon atoms from 1 to 30 are included. An alkyl comprising up to 30 carbon atoms is referred to as a C1-C30 alkyl, likewise, for example, an alkyl comprising up to 12 carbon atoms is a C1-C12 alkyl. Alkyls (and other moieties defined herein) comprising other numbers of carbon atoms are represented similarly. Alkyl groups include, but are not limited to, C1-C30 alkyl, C1-C20 alkyl, C1-C15 alkyl, C1-C10 alkyl, C1-C8 alkyl, C1-C6 alkyl, C1-C4 alkyl, C1-C3 alkyl, C1-C2 alkyl, C2-C8 alkyl, C3-C8 alkyl and C4-C8 alkyl. Representative alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, 1-methylethyl (iso-propyl), n-butyl, i-butyl, s-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), 3-methylhexyl, 2-methylhexyl, ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl, penta-1,4-dienyl, ethynyl, propynyl, but-2-ynyl, but-3-ynyl, pentynyl, hexynyl, and the like. Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted as described below.
“Alkylguanidinyl” refers to a radical of the formula —NRa C(═NRa)N(Ra) 2 where each Ra is, independently, H or an alkyl radical as defined above, provided at least one Ra. is an alkyl radical Unless stated otherwise specifically in the specification, an alkylguanidinyl group is optionally substituted as described below.
“Alkylene” or “alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group. Alkylenes may be saturated or unsaturated (i.e., contains one or more double and/or triple bonds). Representative alkylenes include, but are not limited to, C1-C12 alkylene, C1-C8 alkylene, C1-C6 alkylene, C1-C4 alkylene, C1-C3 alkylene, C1-C2 alkylene, C1 alkylene. Representative alkylene groups include, but are not limited to, methylene, ethylene, propylene, n-butylene, ethenylene, propenylene, n-butenylene, propynylene, n-butynylene, and the like. The alkylene chain is attached to the rest of the molecule through a single or double bond and to the radical group through a single or double bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain is optionally substituted as described below. For example, in certain embodiments the alkylene is substituted with oxo.
“Aminoalkylene” refers to an alkylene as defined above, wherein the hydrocarbon chain is interrupted by (i.e., includes) at least one nitrogen atom. The nitrogen atom(s) may be at any position in the hydrocarbon chain, including the terminal ends (i.e., the nitrogen atom may link the hydrocarbon chain to the rest of the molecule and/or to the radical group). Unless stated otherwise specifically in the specification, an aminoalkylene group is optionally substituted as described below.
“Oxyalkylene” refers to an alkylene as defined above, wherein the hydrocarbon chain is interrupted by (i.e., includes) at least one oxygen atom. The oxygen atom(s) may be at any position in the hydrocarbon chain, including the terminal ends (i.e., the oxygen atom may link the hydrocarbon chain to the rest of the molecule and/or to the radical group). Unless stated otherwise specifically in the specification, an oxyalkylene group is optionally substituted as described below.
“Thioalkylene” refers to an alkylene as defined above, wherein the hydrocarbon chain is interrupted by (i.e., includes) at least one sulfur atom. The sulfur atom(s) may be at any position in the hydrocarbon chain, including the terminal ends (i.e., the sulfur atom may link the hydrocarbon chain to the rest of the molecule and/or to the radical group). Unless stated otherwise specifically in the specification, a thioalkylene group is optionally substituted as described below.
“Alkylaminyl” refers to a radical of the formula —NHRa or —NRaRa where each Ra is, independently, an alkyl radical as defined above. Unless stated otherwise specifically in the specification, an alkylamino group is optionally substituted as described below.
“Fused” refers to any ring structure described herein which is fused to an existing ring structure. When the fused ring is a heterocyclyl ring or a heteroaryl ring, any carbon atom on the existing ring structure which becomes part of the fused heterocyclyl ring or the fused heteroaryl ring may be replaced with a nitrogen atom.
“Halo” or “halogen” refers to bromo, chloro, fluoro or iodo.
“Heterocyclyl”, “heterocycle” or “heterocyclic ring” refers to a stable 3-to 24-membered non-aromatic ring radical comprising 2 to 23 carbon atoms and from one to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous and sulfur. Unless stated otherwise specifically in the specification, the heterocyclyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclyl radical may be partially or fully saturated. Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 12-crown-4, 15-crown-5, 18-crown-6, 21-crown-7, aza-18-crown-6, diaza-18-crown-6, aza-21-crown-7, and diaza-21-crown-7. Unless stated otherwise specifically in the specification, a heterocyclyl group may be optionally substituted.
All the above groups may be either substituted or unsubstituted. The term “substituted” as used herein means any of the above groups (e.g., alkyl, alkylguanidinyl, alkylene, aminoalkylene, oxyalkylene, thioalkylene, alkylaminyl and/or heterocyclyl), may be further functionalized wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atom substituent. Unless stated specifically in the specification, a substituted group may include one or more substituents selected from: amino, oxo, —CO2H, nitrile, nitro, —CONH2, hydroxyl, imino, thio, alkyl, alkylene, alkoxy, alkoxyalkyl, alkylcarbonyl, alkyloxycarbonyl, aryl, aralkyl, arylcarbonyl, aryloxycarbonyl, aralkylcarbonyl, aralkyloxycarbonyl, aryloxy, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, cycloalkyloxycarbonyl, heterocyclyl, heteroaryl, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl groups, triarylsilyl groups, perfluoroalkyl or perfluoroalkoxy, for example, trifluoromethyl or trifluoromethoxy. “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles. For example, “substituted” includes any of the above groups in which one or more hydrogen atoms are replaced with —NRgC(═O)NRgRh, —NRgC(═O)ORh, —NRgSO2Rh, —OC(═O)NRgRh, —ORg, —SRg, —SORg, —SO2Rg, —OSO2Rg, —SO2ORg, ═NSO2Rg, and —SO2NRgRh. “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced with —C(═O)Rg, —C(═O)ORg, —CH2SO2Rg, —CH2SO2NRgRh, —SH, —SRg or —SSRg. In the foregoing, Rg and Rh are the same or different and independently hydrogen, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl. In addition, each of the foregoing substituents may also be optionally substituted with one or more of the above substituents. Furthermore, any of the above groups may be substituted to include one or more internal oxygen or sulfur atoms. For example, an alkyl group may be substituted with one or more internal oxygen atoms to form an ether or polyether group. Similarly, an alkyl group may be substituted with one or more internal sulfur atoms to form a thioether, disulfide, etc.
The terms “antisense oligomer” or “antisense compound” are used interchangeably and refer to a sequence of subunits, each having a base carried on a backbone subunit composed of ribose or other pentose sugar or morpholino group, and where the backbone groups are linked by intersubunit linkages that allow the bases in the compound to hybridize to a target sequence in a nucleic acid (typically an RNA) by Watson-Crick base pairing, to form a nucleic acid:oligomer heteroduplex within the target sequence. The oligomer may have exact sequence complementarity to the target sequence or near complementarity. Such antisense oligomers are designed to block or inhibit translation of the mRNA containing the target sequence, and may be said to be “directed to” a sequence with which it hybridizes.
A “morpholino oligomer” or “PMO” refers to a polymeric molecule having a backbone which supports bases capable of hydrogen bonding to typical polynucleotides, wherein the polymer lacks a pentose sugar backbone moiety, and more specifically a ribose backbone linked by phosphodiester bonds which is typical of nucleotides and nucleosides, but instead contains a ring nitrogen with coupling through the ring nitrogen. An exemplary “morpholino” oligomer comprises morpholino subunit structures linked together by (thio)phosphoramidate or (thio)phosphorodiamidate linkages, joining the morpholino nitrogen of one subunit to the 5′ exocyclic carbon of an adjacent subunit, each subunit comprising a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide. Morpholino oligomers (including antisense oligomers) are detailed, for example, in U.S. Pat. Nos. 5,698,685; 5,217,866; 5,142,047; 5,034,506; 5,166,315; 5,185,444; 5,521,063; 5,506,337 and pending U.S. patent application Ser. Nos. 12/271,036; 12/271,040; and PCT publication number WO/2009/064471 all of which are incorporated herein by reference in their entirety. Representative PMOs include PMOs wherein the intersubunit linkages are linkage (A1).
A “phosphoramidate” group comprises phosphorus having three attached oxygen atoms and one attached nitrogen atom, while a “phosphorodiamidate” group comprises phosphorus having two attached oxygen atoms and two attached nitrogen atoms. In the uncharged or the modified intersubunit linkages of the oligomers described herein and co-pending U.S. Patent Application No. 61/349,783 and Ser. No. 11/801,885, one nitrogen is always pendant to the backbone chain. The second nitrogen, in a phosphorodiamidate linkage, is typically the ring nitrogen in a morpholino ring structure.
“Thiophosphoramidate” or “thiophosphorodiamidate” linkages are phosphoramidate or phosphorodiamidate linkages, respectively, wherein one oxygen atom, typically the oxygen pendant to the backbone, is replaced with sulfur.
“Intersubunit linkage” refers to the linkage connecting two morpholino subunits, for example structure (I).
“Charged”, “uncharged”, “cationic” and “anionic” as used herein refer to the predominant state of a chemical moiety at near-neutral pH, e.g., about 6 to 8. For example, the term may refer to the predominant state of the chemical moiety at physiological pH, that is, about 7.4.
“Lower alkyl” refers to an alkyl radical of one to six carbon atoms, as exemplified by methyl, ethyl, n-butyl, i-butyl, t-butyl, isoamyl, n-pentyl, and isopentyl. In certain embodiments, a “lower alkyl” group has one to four carbon atoms. In other embodiments a “lower alkyl” group has one to two carbon atoms; i.e. methyl or ethyl. Analogously, “lower alkenyl” refers to an alkenyl radical of two to six, preferably three or four, carbon atoms, as exemplified by allyl and butenyl.
A “non-interfering” substituent is one that does not adversely affect the ability of an antisense oligomer as described herein to bind to its intended target. Such substituents include small and/or relatively non-polar groups such as methyl, ethyl, methoxy, ethoxy, or fluoro.
An oligonucleotide or antisense oligomer “specifically hybridizes” to a target polynucleotide if the oligomer hybridizes to the target under physiological conditions, with a Tm greater than 37° C., greater than 45° C., preferably at least 50° C., and typically 60° C.-80° C. or higher. The “Tm” of an oligomer is the temperature at which 50% hybridizes to a complementary polynucleotide. Tm is determined under standard conditions in physiological saline, as described, for example, in Miyada et al., Methods Enzymol. 154:94-107 (1987). Such hybridization may occur with “near” or “substantial” complementary of the antisense oligomer to the target sequence, as well as with exact complementarity.
Polynucleotides are described as “complementary” to one another when hybridization occurs in an antiparallel configuration between two single-stranded polynucleotides. Complementarity (the degree that one polynucleotide is complementary with another) is quantifiable in terms of the proportion of bases in opposing strands that are expected to form hydrogen bonds with each other, according to generally accepted base-pairing rules.
A first sequence is an “antisense sequence” with respect to a second sequence if a polynucleotide whose sequence is the first sequence specifically binds to, or specifically hybridizes with, the second polynucleotide sequence under physiological conditions.
The term “targeting sequence” is the sequence in the oligonucleotide analog that is complementary (meaning, in addition, substantially complementary) to the target sequence in the RNA genome. The entire sequence, or only a portion, of the analog compound may be complementary to the target sequence. For example, in some embodiments an analog having 20 bases, only 12-14 may be targeting sequences. Typically, the targeting sequence is formed of contiguous bases in the analog, but may alternatively be formed of non-contiguous sequences that when placed together, e.g., from opposite ends of the analog, constitute sequence that spans the target sequence.
Target and targeting sequences are described as “complementary” to one another when hybridization occurs in an antiparallel configuration. A targeting sequence may have “near” or “substantial” complementarity to the target sequence and still function for the purpose of the presently described methods, that is, still be “complementary.” Preferably, the oligonucleotide analog compounds employed in the presently described methods have at most one mismatch with the target sequence out of 10 nucleotides, and preferably at most one mismatch out of 20. Alternatively, the antisense oligomers employed have at least 90% sequence homology, and preferably at least 95% sequence homology, with the exemplary targeting sequences as designated herein. For purposes of complementary binding to an RNA target, and as discussed below, a guanine base may be complementary to either a cytosine or uracil RNA base.
A “heteroduplex” refers to a duplex between an oligonucleotide analog and the complementary portion of a target RNA. A “nuclease-resistant heteroduplex” refers to a heteroduplex formed by the binding of an antisense oligomer to its complementary target, such that the heteroduplex is substantially resistant to in vivo degradation by intracellular and extracellular nucleases, such as RNAse H, which are capable of cutting double-stranded RNA/RNA or RNA/DNA complexes.
An agent is “actively taken up by mammalian cells” when the agent can enter the cell by a mechanism other than passive diffusion across the cell membrane. The agent may be transported, for example, by “active transport”, referring to transport of agents across a mammalian cell membrane by e.g. an ATP-dependent transport mechanism, or by “facilitated transport”, referring to transport of antisense agents across the cell membrane by a transport mechanism that requires binding of the agent to a transport protein, which then facilitates passage of the bound agent across the membrane.
The terms “modulating expression” and/or “antisense activity” refer to the ability of an antisense oligomer to either enhance or, more typically, reduce the expression of a given protein, by interfering with the expression or translation of RNA. In the case of reduced protein expression, the antisense oligomer may directly block expression of a given gene, or contribute to the accelerated breakdown of the RNA transcribed from that gene. Morpholino oligomers as described herein are believed to act via the former (steric blocking) mechanism. Preferred antisense targets for steric blocking oligomers include the ATG start codon region, splice sites, regions closely adjacent to splice sites, and 5′-untranslated region of mRNA, although other regions have been successfully targeted using morpholino oligomers.
An “effective amount” or “therapeutically effective amount” refers to an amount of antisense oligomer administered to a mammalian subject, either as a single dose or as part of a series of doses, which is effective to produce a desired therapeutic effect, typically by inhibiting translation of a selected target nucleic acid sequence.
“Treatment” of an individual (e.g. a mammal, such as a human) or a cell is any type of intervention used in an attempt to alter the natural course of the individual or cell. Treatment includes, but is not limited to, administration of a pharmaceutical composition, and may be performed either prophylactically or subsequent to the initiation of a pathologic event or contact with an etiologic agent.
As used herein, “T cells,” also known as “T lymphocytes,” means a subset of lymphocytes defined by their development in the thymus and by heterodimeric receptors (T cell receptors) associated with the proteins of the CD3 complex. Most T lymphocytes have α:β heterodimeric receptors, but some T cells have γ:δ receptors. T cells include several subsets, each with distinct functions: T helper cells (TH cells or CD4+ T cells), cytotoxic T cells (CD8+ T cells, Tc cells, or CTLs), memory T cells, regulatory T cells (Treg cells), and natural killer T cells (NKT cells).
As used herein, an “activated T cells” is a T cell that has been signaled to proliferate and differentiate into an effector cell. Two simultaneous signals are required to activate a T cell. One signal is provided by a peptide bound to an MHC protein on the surface of an antigen presenting cell (APC). The peptide-MHC complex signals through the T cell receptor and its associated proteins. The second signal is provided by co-stimulatory molecules on the APC (e.g., CD80 and CD86), which are recognized by a co-stimulatory receptor (e.g., CD28) on the T cell surface. The combination of the two signals stimulates the T cell to proliferate and begin to differentiate into an effector cell.
As used herein, “B cells,” also known as “B lymphocytes” means a subset of lymphocytes having an immunoglobulin molecule as a cell surface receptor (B cell receptor). Upon activation by an antigen (i.e., binding of the antigen to the B cell receptor), a B cell differentiates into plasma cells producing antibody of the same specificity as its initial receptor.
A. Methods
As noted above, one embodiment of the present disclosure is directed to methods for treatment of lymphocyte-related diseases or conditions, for example T-cell mediated diseases. In general, the methods comprise administering an oligomer comprising a guanidinyl, alkylguanidinyl and/or alkylaminyl moiety to a patient in need thereof. For example, in some embodiments the oligomer is a morpholino oligomer. The guanidinyl, alkylguanidinyl and/or alkylaminyl moiety may be present at any location within the oligomer, and in certain embodiments the guanidinyl, alkylguanidinyl and/or alkylaminyl moiety is bound to the intersubunit linkage of a morpholino oligomer.
In other embodiments, a method for treatment of a lymphocyte-related disease or condition is provided, the method comprising administering an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3′-end of one morpholino ring structure to a 5′-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has the following structure (I):
or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein:
R1 is guanidinyl, alkylguanidinyl or alkylaminyl;
L1 is absent or present, and when present is selected from alkylene, aminoalkylene, oxyalkylene and thioalkylene;
X is, at each occurrence, independently S or O;
Y is, at each occurrence, independently —O— or —NH—; and
Z is an optionally substituted 5, 6 or 7-membered heterocyclic ring.
In certain embodiments of the above, the lymphocyte-related disease or condition is a T-cell related disease or condition.
Various different oligomers are useful for the described methods. For example, morpholino oligomers are employed in various embodiments. In some of these embodiments, the morpholino ring structures have the following structure (i):
wherein B is, at each occurrence, independently a base-pairing moiety, such as A, C, G, T, I, U and the like.
In various embodiments of the above, Z is an optionally substituted 5 or 6-membered heterocyclic ring. For example, in some embodiments Z is pyrrolidinyl, or piperidinyl. In more specific embodiments, Z is piperidinyl.
In even other embodiments, Z has one of the following structures:
For example, in further embodiments Z has the following structure:
The position of the R1-L1 moiety on the Z ring is not particularly limited and various substitution patterns are expected to result in oligomers having the desired properties (i.e., effective delivery to lymphocytes and treatment of lymphocyte-related diseases and/or conditions). In certain embodiments, Z has the following structure:
In any one of the foregoing embodiments, R1 is guanidinyl.
In other of any one of the foregoing embodiments, R1 is alkylguanidinyl. For example, in some embodiments the alkylguanidinyl has the following structure:
wherein R′ is C1-C6alkyl. In further of these embodiments, R′ is methyl.
In still more of any one of the foregoing embodiments, R1 is alkylaminyl. For example, in certain of these embodiments the alkylaminyl is —NHR″, where R″ is C1-C6alkyl. In further of these embodiments, R″ is methyl.
In some embodiments, L1 is absent and R1 is bound directly to the Z ring. In other embodiments, L1 is selected from an appropriate length alkylene, aminoalkylene, oxyalkylene and thioalkylene such that delivery and or activity of the oligomer is optimized.
In various embodiments, X is O. In other embodiments, Y is —O—. In still other embodiments, X is O and Y is —O—.
In addition to one or more intersubunit linkages of structure (I), the oligomers typically contain additional intersubunit linkages of various structures. The structures of the other intersubunit linkages are not particularly limited, provided the oligomer comprises at least one intersubunit linkage of structure (I). In this regard, any of the intersubunit linkages known to one of ordinary skill in the art can be employed, and such intersubunit linkages will be selected to optimize the desired properties of oligomer. In some embodiments, at least one of the intersubunit linkages has the following structure (II):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
R2 and R3 are each independently H or C1-C6alkyl,
X′ is S or O; and
Y′ is —O— or —NH—.
In certain of the above embodiments, R2 and R3 are each methyl. In other embodiments, X′ is O. In more embodiments, Y′ is —O—.
In some of the foregoing embodiments, each intersubunit linkage in the oligomer is either linkage (I) or linkage (II). That is, certain embodiments are directed to oligomers having intersubunit linkages selected from structures (I) and (II), provided at least one intersubunit linkage has structure (I).
In some more embodiments of the above, at least one of the intersubunit linkages has the following structure:
In some other embodiments of the above, at least one of the intersubunit linkages has the following structure:
In even other embodiments of the above, at least one of the intersubunit linkages has the following structure:
In certain embodiments, the lymphocyte-related disease or condition is a T-cell-related disease or condition. In some of these embodiments, the T-cell is an activated T-cell. In other embodiments, the T-cell is a CD4 or CD8 cell.
Various lymphocyte-related diseases or conditions can be treated by the disclosed methods. In various embodiments, the disease or condition is cancer or an autoimmune disease or condition.
In still other embodiments, a method for treatment of a T-cell related disease or condition is provided, the method comprising contacting activated T-cells with an oligomer comprising a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3′-end of one morpholino ring structure to a 5′-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has the following structure (I):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
R1 is guanidinyl, alkylguanidinyl or alkylaminyl;
L1 is absent or present, and when present is selected from alkylene, aminoalkylene, oxyalkylene, oxoalkylene and thioalkylene;
X is, at each occurrence, independently S or O;
Y is, at each occurrence, independently —O— or —NH—; and
Z is an optionally substituted 5, 6 or 7-membered heterocyclic ring.
In various other embodiments of the foregoing, the oligomer and intersubunit linkages are as defined above.
Still other embodiments are directed to use of an oligomer comprising a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3′-end of one morpholino ring structure to a 5′-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has the following structure (I):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
R1 is guanidinyl, alkylguanidinyl or alkylaminyl;
L1 is absent or present, and when present is selected from alkylene, aminoalkylene, oxyalkylene, oxoalkylene and thioalkylene;
X is, at each occurrence, independently S or O;
Y is, at each occurrence, independently —O— or —NH—; and
Z is an optionally substituted 5, 6 or 7-membered heterocyclic ring,
for preparation of a pharmaceutical composition for treatment of a lymphocyte-related disease or condition.
In various other embodiments of the foregoing, the oligomer and intersubunit linkages are as defined above.
Another embodiment provides a method for improving delivery of an oligonucleotide to lymphocytes, such as T cell. The method comprises modifying the oligonucleotide to contain an intersubunit linkage having structure (I).
B. Properties of the Oligomers
As noted above, the present disclosure is directed to methods for treatment of lymphocyte-related diseases or conditions by administration of oligomers comprising various intersubunit linkage modifications, such as linkages comprising guanidinyl, alkylguanidinyl and/or alkylaminyl moieties. In certain embodiments, the oligomer comprises a backbone comprising a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3′-end of one morpholino ring structure to a 5′-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid. The morpholino ring structures may have the following structure (i):
wherein B is, at each occurrence, independently a base-pairing moiety.
Each morpholino ring structure supports a base pairing moiety (B), to form a sequence of base pairing moieties which is typically designed to hybridize to a selected antisense target in a cell or in a subject being treated. The base pairing moiety may be a purine or pyrimidine found in native DNA or RNA (A, G, C, T, or U) or an analog, such as hypoxanthine (the base component of the nucleoside inosine) or 5-methyl cytosine. Analog bases that confer improved binding affinity to the oligomer can also be utilized. Exemplary analogs in this regard include C5-propynyl-modified pyrimidines, 9-(aminoethoxy)phenoxazine (G-clamp) and the like.
The oligomer may be modified, in accordance with an aspect of the invention, to include one or more linkages comprising guanidinyl, alkylguanidinyl and/or alkylaminyl moieties, e.g. up to about 1 per every 2-5 linkages, typically 3-5 per every 10 linkages. Certain embodiments also include one or more linkages comprising guanidinyl, alkylguanidinyl and/or alkylaminyl moieties.
Oligomers for use in antisense applications generally range in length from about 10 to about 40 subunits, more preferably about 15 to 25 subunits. For example, in some embodiments, an oligomer of the invention having 19-20 subunits, a useful length for an antisense oligomer, may ideally have one to seven, e.g. four to six, or three to five linkages comprising guanidinyl, alkylguanidinyl and/or alkylaminyl moieties.
The morpholino subunits may also be linked by non-phosphorus-based intersubunit linkages.
Other oligonucleotide analog linkages which are uncharged in their unmodified state but which could also bear a pendant amine substituent can also be used. For example, in certain embodiments a 5′nitrogen atom on a morpholino ring could be employed in a sulfamide linkage (or a urea linkage, where phosphorus is replaced with carbon or sulfur, respectively).
In some embodiments for antisense applications, the oligomer may be 100% complementary to the nucleic acid target sequence, or it may include mismatches, e.g., to accommodate variants, as long as a heteroduplex formed between the oligomer and nucleic acid target sequence is sufficiently stable to withstand the action of cellular nucleases and other modes of degradation which may occur in vivo. Mismatches, if present, are less destabilizing toward the end regions of the hybrid duplex than in the middle. The number of mismatches allowed will depend on the length of the oligomer, the percentage of G:C base pairs in the duplex, and the position of the mismatch(es) in the duplex, according to well understood principles of duplex stability. Although such an antisense oligomer is not necessarily 100% complementary to the nucleic acid target sequence, it is effective to stably and specifically bind to the target sequence, such that a biological activity of the nucleic acid target, e.g., expression of encoded protein(s), is modulated.
The stability of the duplex formed between an oligomer and the target sequence is a function of the binding Tm and the susceptibility of the duplex to cellular enzymatic cleavage. The Tm of an antisense compound with respect to complementary-sequence RNA may be measured by conventional methods, such as those described by Hames et al., Nucleic Acid Hybridization, IRL Press, 1985, pp. 107-108 or as described in Miyada C. G. and Wallace R. B., 1987, Oligonucleotide hybridization techniques, Methods Enzymol. Vol. 154 pp. 94-107.
In some embodiments, each antisense oligomer has a binding Tm, with respect to a complementary-sequence RNA, of greater than human body temperature or in other embodiments greater than 50° C. In other embodiments Tm's are in the range 60-80° C. or greater. According to well known principles, the Tm of an oligomer compound, with respect to a complementary-based RNA hybrid, can be increased by increasing the ratio of C:G paired bases in the duplex, and/or by increasing the length (in base pairs) of the heteroduplex. At the same time, for purposes of optimizing cellular uptake, it may be advantageous to limit the size of the oligomer. For this reason, compounds that show high Tm (50° C. or greater) at a length of 20 bases or less are generally preferred over those requiring greater than 20 bases for high Tm values. For some applications, longer oligomers, for example longer than 20 bases may have certain advantages. For example, in certain embodiments longer oligomers may find particular utility for use in exon skipping or splice modulation.
The targeting sequence bases may be normal DNA bases or analogues thereof, e.g., uracil and inosine that are capable of Watson-Crick base pairing to target-sequence RNA bases.
The oligomers may also incorporate guanine bases in place of adenine when the target nucleotide is a uracil residue. This is useful when the target sequence varies across different target alleles or viral species and the variation at any given nucleotide residue is either cytosine or uracil. By utilizing guanine in the targeting oligomer at the position of variability, the well-known ability of guanine to base pair with uracil (termed C/U:G base pairing) can be exploited. By incorporating guanine at these locations, a single oligomer can effectively target a wider range of RNA target variability.
The compounds (e.g., oligomers, morpholino subunits, intersubunit linkages, etc.) may exist in different isomeric forms, for example structural isomers (e.g., tautomers). With regard to stereoisomers, the compounds may have chiral centers and may occur as racemates, enantiomerically enriched mixtures, individual enantiomers, mixture or diastereomers or individual diastereomers. All such isomeric forms are included within the present invention, including mixtures thereof. The compounds may also possess axial chirality which may result in atropisomers. Furthermore, some of the crystalline forms of the compounds may exist as polymorphs, which are included in the present invention. In addition, some of the compounds may also form solvates with water or other organic solvents. Such solvates are similarly included within the scope of this invention.
The oligomers described herein may be used in methods of inhibiting production of a protein or replication of a virus. Accordingly, in one embodiment a nucleic acid encoding such a protein is exposed to an oligomer as disclosed herein. In further embodiments of the foregoing, the antisense oligomer comprises one or more intersubunit linkages comprising a guanidinyl, alkylguanidinyl and/or alkylaminyl moiety, as disclosed herein, and the base pairing moieties B form a sequence effective to hybridize to a portion of the nucleic acid at a location effective to inhibit production of the protein. In one embodiment, the location is an ATG start codon region of an mRNA, a splice site of a pre-mRNA, or a viral target sequence as described below.
In one embodiment, the oligomer has a Tm with respect to binding to the target sequence of greater than about 50° C., and it is taken up by mammalian cells or bacterial cells.
The preparation and properties of morpholino oligomers is described in more detail below and in U.S. Pat. No. 5,185,444 and WO/2009/064471, each of which is hereby incorporated by reference in their entirety.
C. Formulation and Administration of the Oligomers
The present disclosure also provides for formulation and delivery of the disclosed oligomers (e.g., for treatment of lymphocyte-related diseases and/or conditions). Accordingly, in one embodiment the present disclosure is directed to a composition comprising an oligomer as disclosed herein and a pharmaceutically acceptable vehicle. Other embodiments are directed to use of such a composition for treatment of a lymphocyte-related disease and/or condition.
Effective delivery of the antisense oligomer to the target nucleic acid is an important aspect of treatment. Routes of antisense oligomer delivery include, but are not limited to, various systemic routes, including oral and parenteral routes, e.g., intravenous, subcutaneous, intraperitoneal, and intramuscular, as well as inhalation, transdermal and topical delivery. The appropriate route may be determined by one of skill in the art, as appropriate to the condition of the subject under treatment. For example, the oligomer may be delivered directly to the bloodstream.
The antisense oligomer may be administered in any convenient vehicle which is physiologically and/or pharmaceutically acceptable. Such a composition may include any of a variety of standard pharmaceutically acceptable carriers employed by those of ordinary skill in the art. Examples include, but are not limited to, saline, phosphate buffered saline (PBS), water, aqueous ethanol, emulsions, such as oil/water emulsions or triglyceride emulsions, tablets and capsules. The choice of suitable physiologically acceptable carrier will vary depending upon the chosen mode of administration.
The compounds (e.g., oligomers) of the present invention may generally be utilized as the free acid or free base. Alternatively, the compounds of this invention may be used in the form of acid or base addition salts. Acid addition salts of the free amino compounds of the present invention may be prepared by methods well known in the art, and may be formed from organic and inorganic acids. Suitable organic acids include maleic, fumaric, benzoic, ascorbic, succinic, methanesulfonic, acetic, trifluoroacetic, oxalic, propionic, tartaric, salicylic, citric, gluconic, lactic, mandelic, cinnamic, aspartic, stearic, palmitic, glycolic, glutamic, and benzenesulfonic acids. Suitable inorganic acids include hydrochloric, hydrobromic, sulfuric, phosphoric, and nitric acids. Base addition salts included those salts that form with the carboxylate anion and include salts formed with organic and inorganic cations such as those chosen from the alkali and alkaline earth metals (for example, lithium, sodium, potassium, magnesium, barium and calcium), as well as the ammonium ion and substituted derivatives thereof (for example, dibenzylammonium, benzylammonium, 2-hydroxyethylammonium, and the like). Thus, the term “pharmaceutically acceptable salt” of structure (I) is intended to encompass any and all acceptable salt forms.
In addition, prodrugs are also included within the context of this invention. Prodrugs are any covalently bonded carriers that release a compound of structure (I) in vivo when such prodrug is administered to a patient. Prodrugs are generally prepared by modifying functional groups of the active moiety in a way such that the modification is cleaved, either by routine manipulation or in vivo, yielding the parent compound. Prodrugs include, for example, compounds of this invention wherein hydroxy, amine or sulfhydryl groups are bonded to any group that, when administered to a patient, cleaves to form the hydroxy, amine or sulfhydryl groups. Thus, representative examples of prodrugs include (but are not limited to) acetate, formate and benzoate derivatives of alcohol and amine functional groups of the compounds of structure (I). Further, in the case of a carboxylic acid (—COOH), esters may be employed, such as methyl esters, ethyl esters, and the like.
In some instances, liposomes may be employed to facilitate uptake of the antisense oligonucleotide into cells. (See, e.g., Williams, S. A., Leukemia 10(12):1980-1989, 1996; Lappalainen et al., Antiviral Res. 23:119, 1994; Uhlmann et al., antisense oligonucleotides: a new therapeutic principle, Chemical Reviews, Volume 90, No. 4, pages 544-584, 1990; Gregoriadis, G., Chapter 14, Liposomes, Drug Carriers in Biology and Medicine, pp. 287-341, Academic Press, 1979). Hydrogels may also be used as vehicles for antisense oligomer administration, for example, as described in WO 93/01286. Alternatively, the oligonucleotides may be administered in microspheres or microparticles. (See, e.g., Wu, G. Y. and Wu, C. H., J. Biol. Chem. 262:4429-4432, 1987). Alternatively, the use of gas-filled microbubbles complexed with the antisense oligomers can enhance delivery to target tissues, as described in U.S. Pat. No. 6,245,747. Sustained release compositions may also be used. These may include semipermeable polymeric matrices in the form of shaped articles such as films or microcapsules.
In one embodiment, antisense inhibition is effective in treating a lymphocyte-related disease or conditions, by contacting lymphocytes, such as T cells, with an antisense agent described herein. The antisense agent is administered to a mammalian subject, e.g., human or domestic animal, in a suitable pharmaceutical carrier.
In one aspect of the method, the subject is a human subject, e.g., a patient diagnosed as having a lymphocyte-related disease or condition. The condition of a patient may also dictate prophylactic administration of an antisense oligomer of the invention, e.g. in the case of a patient who (1) is immunocompromised; (2) is a burn victim; (3) has an indwelling catheter; or (4) is about to undergo or has recently undergone surgery. In one preferred embodiment, the oligomer is a phosphorodiamidate morpholino oligomer, contained in a pharmaceutically acceptable carrier, and is delivered orally. In another preferred embodiment, the oligomer is a phosphorodiamidate morpholino oligomer, contained in a pharmaceutically acceptable carrier, and is delivered intravenously (i.v.).
In another application of the method, the subject is a livestock animal, e.g., a chicken, turkey, pig, cow, horse or goat, etc, and the treatment is either prophylactic or therapeutic.
In one embodiment, the antisense compound is administered in an amount and manner effective to result in a peak blood concentration of at least 200-400 nM antisense oligomer. Typically, one or more doses of antisense oligomer are administered, generally at regular intervals, for a period of about one to two weeks. Preferred doses for oral administration are from about 1-1000 mg oligomer per 70 kg. In some cases, doses of greater than 1000 mg oligomer/patient may be necessary. For i.v. administration, preferred doses are from about 0.5 mg to 1000 mg oligomer per 70 kg. The antisense oligomer may be administered at regular intervals for a short time period, e.g., daily for two weeks or less. However, in some cases the oligomer is administered intermittently over a longer period of time. Administration may be followed by, or concurrent with, administration of an antibiotic or other therapeutic treatment. The treatment regimen may be adjusted (dose, frequency, route, etc.) as indicated, based on the results of immunoassays, other biochemical tests and physiological examination of the subject under treatment.
An effective in vivo treatment regimen using the antisense oligonucleotides of the invention may vary according to the duration, dose, frequency and route of administration, as well as the condition of the subject under treatment. Accordingly, such in vivo therapy will often require monitoring by tests appropriate to the particular type of disease or condition under treatment, and corresponding adjustments in the dose or treatment regimen, in order to achieve an optimal therapeutic outcome. Treatment may be monitored, e.g., by general indicators of disease, such as complete blood count (CBC), nucleic acid detection methods, immunodiagnostic tests, or detection of heteroduplex.
The efficacy of an in vivo administered antisense oligomer of the invention in treating lymphocyte-related diseases and/or conditions may be determined from biological samples (tissue, blood, urine etc.) taken from a subject prior to, during and subsequent to administration of the antisense oligomer. Assays of such samples include (1) monitoring the presence or absence of heteroduplex formation with target and non-target sequences, using procedures known to those skilled in the art, e.g., an electrophoretic gel mobility assay.
D. Preparation of the Oligomers
The morpholino subunits, the modified intersubunit linkages and oligomers comprising the same can be prepared as described in the examples and in U.S. Pat. Nos. 5,185,444; 7,943,762; 8,076,476; and 8,299,206 and co-pending U.S. application Ser. No. 13/118,298, which are hereby incorporated by reference in their entirety. The morpholino subunits can be prepared according to the following general Reaction Scheme I.
Referring to Reaction Scheme 1, wherein B represents a base pairing moiety and PG represents a protecting group, the morpholino subunits may be prepared from the corresponding ribinucleoside (1) as shown. The morpholino subunit (2) may be optionally protected by reaction with a suitable protecting group precursor, for example trityl chloride. The 3′ protecting group is generally removed during solid-state oligomer synthesis as described in more detail below. The base pairing moiety may be suitably protected for solid-phase oligomer synthesis. Suitable protecting groups include benzoyl for adenine and cytosine, phenylacetyl for guanine, and pivaloyloxymethyl for hypoxanthine (I). The pivaloyloxymethyl group can be introduced onto the N1 position of the hypoxanthine heterocyclic base. Although an unprotected hypoxanthine subunit, may be employed, yields in activation reactions are far superior when the base is protected. Other suitable protecting groups include those disclosed in U.S. Pat. No. 8,076,476, which is hereby incorporated by reference in its entirety.
Reaction of 3 with the activated phosphorous compound 4a or 4b results in morpholino subunits having the desired linkage moiety (5a or 5b). It should be noted that the R1 and/or L1 moieties may also be installed on the heterocyclic ring Z after formation of the P—C bond or even after the subunit has been incorporated into an oligomer.
Compounds of structure 4a or 4b can be prepared using any number of methods known to those of skill in the art, including those described in the examples. Coupling with the morpholino moiety then proceeds as outlined above.
Compounds of structure 5a or 5b can be used in solid-phase automated oligomer synthesis for preparation of oligomers comprising the intersubunit linkages. Such methods are well known in the art. Briefly, a compound of structure 5a or 5b may be modified at the 5′ end to contain a linker to a solid support. Once supported, the protecting group of 5a or 5b (e.g., trityl) is removed and the free amine is reacted with an activated phosphorous moiety of a second compound of structure 5 (or analogue thereof). This sequence is repeated until the desired length oligo is obtained. The protecting group in the terminal 5′ end may either be removed or left on if a 5′-modification is desired. The oligo can be removed from the solid support using any number of methods, or example treatment with a base to cleave the linkage to the solid support.
The preparation of modified morpholino subunits and morpholino oligomers are described in more detail in the Examples. The morpholino oligomers containing any number of modified linkages may be prepared using methods described herein, methods known in the art and/or described by reference herein.
E. Antisense Targets of the Oligomers
The present applicants have unexpectedly discovered that the described oligomers (e.g., oligomers comprising gaunidinyl, alkylguanidinyl and/or alkylaminyl substituents on one or more intersubunit linkage) are highly effective for delivery to lymphocytes, such as T cells. Accordingly, the described methods can be employed for treatment of any number of lymphocyte related diseases and/or conditions. In this regard, one of ordinary skill in the art will recognize the various diseases and/or conditions treatable with the oligomers and the associated target (e.g., gene sequence).
In general, the oligomers comprise a sequence targeted against a gene associated with a lymphocyte related disease or condition. Typical targeting sites within such genes include, but are not limited to start codons or splice junction sites, for example an ATG start codon region of an mRNA or a splice site of a pre-mRNA. Accordingly, certain oligomers of the invention comprise or consist of base sequences which specifically hybridize to such gene targets. In some embodiments, the oligomers have at least 90% sequence homology or at least 95% sequence homology, with the targeting site. Exemplary targets are provided in Table 1. Other targets are derivable by one of ordinary skill in the art.
This description is not meant to limit the invention in any way but serves to exemplify the range of human and animal disease conditions that can be addressed using oligomers comprising the modified intersubunit linkages described herein.
EXAMPLESUnless otherwise noted, all chemicals were obtained from Sigma-Aldrich-Fluka. Benzoyl adenosine, benzoyl cytidine, and phenylacetyl guanosine were obtained from Carbosynth Limited, UK.
Synthesis of PMO and PMO containing further linkage modifications as described herein was done using methods known in the art and described in pending U.S. application Ser. Nos. 12/271,036 and 12/271,040 and PCT publication number WO/2009/064471, which are hereby incorporated by reference in their entirety.
PMO with a 3′ trityl modification are synthesized essentially as described in PCT publication number WO/2009/064471 with the exception that the detritylation step is omitted.
Example 1 tert-butyl(2,2,2-trifluoroacetamido)piperidine-1-carboxylateTo a suspension of tert-butyl 4-aminopiperidine-1-carboxylate (48.7 g, 0.243 mol) and DIPEA (130 mL, 0.749 mol) in DCM (250 mL) was added ethyl trifluoroacetate (35.6 mL, 0.300 mol) dropwise while stirring. After 20 hours, the solution was washed with citric acid solution (200 mL×3, 10% w/v aq) and sodium bicarbonate solution (200 mL×3, conc aq), dried (MgSO4), and filtered through silica (24 g). The silica was washed with DCM and the combined eluant was partially concentrated (100 mL), and used directly in the next step. APCI/MS calcd. for C12H19F3N2O3 296.1, found m/z=294.9 (M−1).
Example 2 2,2,2-trifluoro-N-(piperidin-4-yl)acetamide HydrochlorideTo a stirred DCM solution of the title compound of Example 1 (100 mL) was added dropwise a solution of hydrogen chloride (250 mL, 1.0 mol) in 1,4-dioxane (4 M). Stirring was continued for 6 hours, then the suspension was filtered, and the solid washed with diethyl ether (500 mL) to afford the title compound (54.2 g, 96% yield) as a white solid. APCI/MS calcd. for C7H11F3N2O 196.1, found m/z=196.9 (M+1).
Example 3 (4-(2,2,2-trifluoroacetamido)piperidin-1-yl)phosphonic DichlorideTo a cooled (ice/water bath) suspension of the title compound of Example 2 (54.2 g, 0.233 mol) in DCM (250 mL) was added dropwise phosphorus oxychloride (23.9 mL, 0.256 mol) and DIPEA (121.7 mL, 0.699 mol) and stirred. After 15 minutes, the bath was removed and with continued stirring the mixture allowed to warm to ambient temperature. After 1 hour, the mixture was partially concentrated (100 mL), the suspension filtered, and the solid washed with diethyl ether to afford the title compound (43.8 g, 60% yield) as a white solid. The eluant was partially concentrated (100 mL), the resulting suspension filtered, and the solid washed with diethyl ether to afford additional title compound (6.5 g, 9% yield). ESI/MS calcd. for 1-(4-nitrophenyl)piperazine derivative C17H22ClF3N5O4P 483.1, found m/z=482.1 (M−1).
Example 4 ((2S,6S)-6-((R)-5-methyl-2,6-dioxo-1,2,3,6-tetrahydropyridin-3-yl)-4-tritylmorpholin-2-yl)methyl (4-(2,2,2-trifluoroacetamido)piperidin-1-yl)phosphonochloridateTo a stirred, cooled (ice/water bath) solution of the title compound of Example 3 (29.2 g, 93.3 mmol) in DCM (100 mL) was added dropwise over 10 minutes a DCM solution (100 mL) of Mo(Tr)T # (22.6 g, 46.7 mmol), 2,6-Lutidine (21.7 mL, 187 mmol), and 4-(dimethylamino)pyridine (1.14 g, 9.33 mmol). The bath was allowed to warm to ambient temperature. After 15 hours, the solution was washed with a citric acid solution (200 mL×3, 10% w/v aq), dried (MgSO4), concentrated, and the crude oil was loaded directly onto column. Chromatography [SiO2 column (120 g), hexanes/EtOAc eluant (gradient 1:1 to 0:1), repeated ×3] fractions were concentrated to provide the title compound (27.2 g, 77% yield) as a white solid. ESI/MS calcd. for the 1-(4-nitrophenyl)piperazine derivative C46H50F3N8O8P 930.3, found m/z=929.5 (M−1).
Example 5 ((2S,6R)-6-(6-benzamido-9H-purin-9-yl)-4-tritylmorpholin-2-yl)methyl (4-(2,2,2-trifluoroacetamido)piperidin-1-yl)phosphonochloridateThe title compound was synthesized in a manner analogous to that described in Example 4 to afford the title compound (15.4 g, 66% yield) as a white solid. ESI/MS calcd. for 1-(4-nitrophenyl)piperazine derivative C53H53F3N11O7P 1043.4, found m/z=1042.5 (M−1).
Example 6 Global Guanidinylation of OligomersAn appropriate amount of an oligomer containing an aminopiperidine linkage (or methylated analogue thereof) prepared as described above (25 mg, 2.8 μmol) was weighed into a vial (6 ml). 1H-Pyrozole-1-carboxamidine chloride (15 mg, 102 μmol) and potassium carbonate (20 mg, 0.15 mmol) were added to the vial. Water was added (500 ul), and the reaction mixture was stirred at room temperature overnight (about 18 hours). Reaction completion was determined by MALDI.
Once complete, the reaction was diluted with 1% ammonia in water (10 ml) and loaded on to an SPE column (2 cm). The vial was rinsed with 1% ammonia solution (2×2 ml), and the SPE column was washed with 1% ammonia in water (3×6 ml). Product was eluted with 45% acetonitrile in 1% ammonia in water (6 ml). Fractions containing oligomer were identified by UV optical density measurement. Product was isolated by lyophilization. Purity and identity were determined by MALDI and HPLC (C-18 and/or SAX).
Example 7 Preparation of Morpholino OligomersPreparation of trityl piperazine phenyl carbamate 35 (see
Preparation of carbamate alcohol 36: Sodium hydride (1.2 eq) was suspended in 1-methyl-2-pyrrolidinone (32 mL/g sodium hydride). To this suspension were added triethylene glycol (10.0 eq) and compound 35 (1.0 eq). The resulting slurry was heated to 95° C. Upon reaction completion (1-2 hr), the mixture was cooled to 20° C. To this mixture was added 30% dichloromethane/methyl tert-butyl ether (v:v) and water. The product-containing organic layer was washed successively with aqueous NaOH, aqueous succinic acid, and saturated aqueous sodium chloride. The product 36 was isolated by crystallization from dichloromethane/methyl tert-butyl ether/heptane. Yield=90%.
Preparation of Tail acid 37: To a solution of compound 36 in tetrahydrofuran (7 mL/g 36) was added succinic anhydride (2.0 eq) and DMAP (0.5 eq). The mixture was heated to 50° C. Upon reaction completion (5 hr), the mixture was cooled to 20° C. and adjusted to pH 8.5 with aqueous NaHCO3. Methyl tert-butyl ether was added, and the product was extracted into the aqueous layer. Dichloromethane was added, and the mixture was adjusted to pH 3 with aqueous citric acid. The product-containing organic layer was washed with a mixture of pH=3 citrate buffer and saturated aqueous sodium chloride. This dichloromethane solution of 37 was used without isolation in the preparation of compound 38.
Preparation of 38: To the solution of compound 37 was added N-hydroxy-5-norbornene-2,3-dicarboxylic acid imide (HONB) (1.02 eq), 4-dimethylaminopyridine (DMAP) (0.34 eq), and then 1-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) (1.1 eq). The mixture was heated to 55° C. Upon reaction completion (4-5 hr), the mixture was cooled to 20° C. and washed successively with 1:1 0.2 M citric acid/brine and brine. The dichloromethane solution underwent solvent exchange to acetone and then to N,N-dimethylformamide, and the product was isolated by precipitation from acetone/N,N-dimethylformamide into saturated aqueous sodium chloride. The crude product was reslurried several times in water to remove residual N,N-dimethylformamide and salts. Yield=70% of 38 from compound 36. Introduction of the activated “Tail” onto the disulfide anchor-resin was performed in NMP by the procedure used for incorporation of the subunits during solid phase synthesis.
Preparation of the Solid Support for Synthesis of Morpholino Oligomers: This procedure was performed in a silanized, jacketed peptide vessel (custom made by ChemGlass, NJ, USA) with a coarse porosity (40-60 μm) glass frit, overhead stirrer, and 3-way Teflon stopcock to allow N2 to bubble up through the frit or a vacuum extraction. Temperature control was achieved in the reaction vessel by a circulating water bath.
The resin treatment/wash steps in the following procedure consist of two basic operations: resin fluidization and solvent/solution extraction. For resin fluidization, the stopcock was positioned to allow N2 flow up through the frit and the specified resin treatment/wash was added to the reactor and allowed to permeate and completely wet the resin. Mixing was then started and the resin slurry mixed for the specified time. For solvent/solution extraction, mixing and N2 flow were stopped and the vacuum pump was started and then the stopcock was positioned to allow evacuation of resin treatment/wash to waste. All resin treatment/wash volumes were 15 mL/g of resin unless noted otherwise.
To aminomethylpolystyrene resin (100-200 mesh; ˜1.0 mmol/g N2 substitution; 75 g, 1 eq, Polymer Labs, UK, part #1464-X799) in a silanized, jacketed peptide vessel was added 1-methyl-2-pyrrolidinone (NMP; 20 ml/g resin) and the resin was allowed to swell with mixing for 1-2 hr. Following evacuation of the swell solvent, the resin was washed with dichloromethane (2×1-2 min), 5% diisopropylethylamine in 25% isopropanol/dichloromethane (2×3-4 min) and dichloromethane (2×1-2 min). After evacuation of the final wash, the resin was fluidized with a solution of disulfide anchor 34 in 1-methyl-2-pyrrolidinone (0.17 M; 15 mL/g resin, ˜2.5 eq) and the resin/reagent mixture was heated at 45° C. for 60 hr. On reaction completion, heating was discontinued and the anchor solution was evacuated and the resin washed with 1-methyl-2-pyrrolidinone (4×3-4 min) and dichloromethane (6×1-2 min). The resin was treated with a solution of 10% (v/v) diethyl dicarbonate in dichloromethane (16 mL/g; 2×5-6 min) and then washed with dichloromethane (6×1-2 min). The resin 39 (see
Determination of the Loading of Aminomethylpolystyrene-disulfide resin: The loading of the resin (number of potentially available reactive sites) is determined by a spectrometric assay for the number of triphenylmethyl (trityl) groups per gram of resin.
A known weight of dried resin (25±3 mg) is transferred to a silanized 25 ml volumetric flask and ˜5 mL of 2% (v/v) trifluoroacetic acid in dichloromethane is added. The contents are mixed by gentle swirling and then allowed to stand for 30 min. The volume is brought up to 25 mL with additional 2% (v/v) trifluoroacetic acid in dichloromethane and the contents thoroughly mixed. Using a positive displacement pipette, an aliquot of the trityl-containing solution (500 μL) is transferred to a 10 mL volumetric flask and the volume brought up to 10 mL with methanesulfonic acid.
The trityl cation content in the final solution is measured by UV absorbance at 431.7 nm and the resin loading calculated in trityl groups per gram resin (μmol/g) using the appropriate volumes, dilutions, extinction coefficient (ε: 41 μmol-1 cm-1) and resin weight. The assay is performed in triplicate and an average loading calculated.
The resin loading procedure in this example will provide resin with a loading of approximately 500 μmol/g. A loading of 300-400 in μmol/g was obtained if the disulfide anchor incorporation step is performed for 24 hr at room temperature.
Tail loading: Using the same setup and volumes as for the preparation of aminomethylpolystyrene-disulfide resin, the Tail can be introduced into the molecule. For the coupling step, a solution of 38 (0.2 M) in NMP containing 4-ethylmorpholine (NEM, 0.4 M) was used instead of the disulfide anchor solution. After 2 hr at 45° C., the resin 39 was washed twice with 5% diisopropylethylamine in 25% isopropanol/dichloromethane and once with DCM. To the resin was added a solution of benzoic anhydride (0.4 M) and NEM (0.4 M). After 25 min, the reactor jacket was cooled to room temperature, and the resin washed twice with 5% diisopropylethylamine in 25% isopropanol/dichloromethane and eight times with DCM. The resin 40 was filtered and dried under high vacuum. The loading for resin 40 is defined to be the loading of the original aminomethylpolystyrene-disulfide resin 39 used in the Tail loading.
Solid Phase Synthesis: Morpholino Oligomers were prepared on a Gilson AMS-422 Automated Peptide Synthesizer in 2 mL Gilson polypropylene reaction columns (Part #3980270). An aluminum block with channels for water flow was placed around the columns as they sat on the synthesizer. The AMS-422 will alternatively add reagent/wash solutions, hold for a specified time, and evacuate the columns using vacuum.
For oligomers in the range up to about 25 subunits in length, aminomethylpolystyrene-disulfide resin with loading near 500 μmol/g of resin is preferred. For larger oligomers, aminomethylpolystyrene-disulfide resin with loading of 300-400 μmol/g of resin is preferred. If a molecule with 5′-Tail is desired, resin that has been loaded with Tail is chosen with the same loading guidelines.
The following reagent solutions were prepared:
Detritylation Solution: 10% Cyanoacetic Acid (w/v) in 4:1 dichloromethane/acetonitrile; Neutralization Solution: 5% Diisopropylethylamine in 3:1 dichloromethane/isopropanol; Coupling Solution: 0.18 M (or 0.24 M for oligomers having grown longer than 20 subunits) activated Morpholino Subunit of the desired base and linkage type and 0.4 M N ethylmorpholine, in 1,3-dimethylimidazolidinone. Dichloromethane (DCM) was used as a transitional wash separating the different reagent solution washes.
On the synthesizer, with the block set to 42° C., to each column containing 30 mg of aminomethylpolystyrene-disulfide resin (or Tail resin) was added 2 mL of 1-methyl-2-pyrrolidinone and allowed to sit at room temperature for 30 min. After washing with 2 times 2 mL of dichloromethane, the following synthesis cycle was employed:
The sequences of the individual oligomers were programmed into the synthesizer so that each column receives the proper coupling solution (A,C,G,T,I) in the proper sequence. When the oligomer in a column had completed incorporation of its final subunit, the column was removed from the block and a final cycle performed manually with a coupling solution comprised of 4-methoxytriphenylmethyl chloride (0.32 M in DMI) containing 0.89 M 4-ethylmorpholine.
Cleavage from the resin and removal of bases and backbone protecting groups: After methoxytritylation, the resin was washed 8 times with 2 mL 1-methyl-2-pyrrolidinone. One mL of a cleavage solution consisting of 0.1 M 1,4-dithiothreitol (DTT) and 0.73 M triethylamine in 1-methyl-2-pyrrolidinone was added, the column capped, and allowed to sit at room temperature for 30 min. After that time, the solution was drained into a 12 mL Wheaton vial. The greatly shrunken resin was washed twice with 300 μL of cleavage solution. To the solution was added 4.0 mL conc aqueous ammonia (stored at −20° C.), the vial capped tightly (with Teflon lined screw cap), and the mixture swirled to mix the solution. The vial was placed in a 45° C. oven for 16-24 hr to effect cleavage of base and backbone protecting groups.
Initial Oligomer Isolation: The vialed ammonolysis solution was removed from the oven and allowed to cool to room temperature. The solution was diluted with 20 mL of 0.28% aqueous ammonia and passed through a 2.5×10 cm column containing Macroprep HQ resin (BioRad). A salt gradient (A: 0.28% ammonia with B: 1 M sodium chloride in 0.28% ammonia; 0-100% B in 60 min) was used to elute the methoxytrityl containing peak. The combined fractions were pooled and further processed depending on the desired product.
Demethoxytritylation of Morpholino Oligomers: The pooled fractions from the Macroprep purification were treated with 1 M H3PO4 to lower the pH to 2.5. After initial mixing, the samples sat at room temperature for 4 min, at which time they are neutralized to pH 10-11 with 2.8% ammonia/water. The products were purified by solid phase extraction (SPE).
Amberchrome CG-300M (Rohm and Haas; Philadelphia, Pa.) (3 mL) is packed into 20 mL fritted columns (BioRad Econo-Pac Chromatography Columns (732-1011)) and the resin rinsed with 3 mL of the following: 0.28% NH4OH/80% acetonitrile; 0.5M NaOH/20% ethanol; water; 50 mM H3PO4/80% acetonitrile; water; 0.5 NaOH/20% ethanol; water; 0.28% NH4OH.
The solution from the demethoxytritylation was loaded onto the column and the resin rinsed three times with 3-6 mL 0.28% aqueous ammonia. A Wheaton vial (12 mL) was placed under the column and the product eluted by two washes with 2 mL of 45% acetonitrile in 0.28% aqueous ammonia. The solutions were frozen in dry ice and the vials placed in a freeze dryer to produce a fluffy white powder. The samples were dissolved in water, filtered through a 0.22 micron filter (Pall Life Sciences, Acrodisc 25 mm syringe filter, with a 0.2 micron HT Tuffryn membrane) using a syringe and the Optical Density (OD) was measured on a UV spectrophotometer to determine the OD units of oligomer present, as well as dispense sample for analysis. The solutions were then placed back in Wheaton vials for lyophilization.
Analysis of Morpholino Oligomers: MALDI-TOF mass spectrometry was used to determine the composition of fractions in purifications as well as provide evidence for identity (molecular weight) of the oligomers. Samples were run following dilution with solution of 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid), 3,4,5-trihydoxyacetophenone (THAP) or alpha-cyano-4-hydoxycinnamic acid (HCCA) as matrices.
Cation exchange (SCX) HPLC was performed using a Dionex ProPac SCX-10, 4×250 mm column (Dionex Corporation; Sunnyvale, Calif.) using 25 mM pH=5 sodium acetate 25% acetonitrile (Buffer A) and 25 mM pH=5 sodium acetate 25% acetonitrile 1.5 M potassium chloride (buffer B) (Gradient 10-100% B in 15 min) or 25 mM KH2PO4 25% acetonitrile at pH=3.5 (buffer A) and 25 mM KH2PO4 25% acetonitrile at pH=3.5 with 1.5 M potassium chloride (buffer B) (Gradient 0-35% B in 15 min). The former system was used for positively charged oligomers that do not have a peptide attached, while the latter was used for peptide conjugates.
Purification of Morpholino Oligomers by Cation Exchange Chromatography: The sample is dissolved in 20 mM sodium acetate, pH=4.5 (buffer A) and applied to a column of Source 30 cation exchange resin (GE Healthcare) and eluted with a gradient of 0.5 M sodium chloride in 20 mM sodium acetate and 40% acetonitrile, pH=4.5 (buffer B). The pooled fractions containing product are neutralized with conc aqueous ammonia and applied to an Amberchrome SPE column. The product is eluted, frozen, and lyophilized as above.
Example 8 In Vitro and In Vivo Testing of the OligomersA PMO (5′-GCT ATT ACC TTA ACC CAG-3; SEQ ID NO: 1) designed to restore correct splicing in the enhanced green fluorescent protein (EGFP) gene was modified at the intersubunit linkage and/or the 5′ and/or 3′ end to produce modified PMOs, which were evaluated for their splice-correction activity and tissue distribution in the EGFP-654 transgenic mouse model (Sazani, Gemignani et al. 2002). In this model, the EGFP-654 gene encoding for functional EGFP is interrupted by an aberrantly-spliced mutated intron, and cellular uptake of EGFP targeted PMOs, such as SEQ ID NO: 1, can be evaluated by RT-PCR detection of the restored EGFP-654 splice product in tissues or detection of functional EGFP by fluorescence.
Sequences of the oligomers employed for the experiments described herein are presented in Table 2. The oligomers typically comprise a piperazine linker on the 5′ end and either an ethylene glycol trimer (EG3) or guanidinyl terminal group linked thereto. The 3′ end is either unmodified (H) or comprises a trityl, gaunidinyl or peptide moiety. An “*” indicates the presence of a modified intersubunit linkage, the structure of which is provided in Table 3. All other linkages are PMO.
EGFP-654 transgenic mice (14-28 weeks old, female) were injected by tail vein I.V. with a G-pip modified oligomer (NG-10-0389) or a peptide-modified oligomer (NG-08-0524, X=aminohexanoic acid, B=beta-alanine) at doses of 2.5 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg (PBS vehicle). Tissues were harvested 7 days post injection and analyzed for presence of the oligomers.
Splenocytes from an EGFP-654 reporter mouse were harvested and a cell suspension was made. Cells were CD3/CD28 stimulated in the presence of the oligomers from Table 2 for 24 h at 37° C. Cells were harvested from the plate and run through a flow cytometer for detection of EGFP and T and B cell markers. Activated and resting T cells were delineated using CD25 as the activation marker. Successful delivery to T cells is indicated by the presence of EGFP within the cell (i.e., EGFP positive cells).
EGFP-654 reporter mice were injected with various oligomers from Table 2 as described above. Splenocytes were harvested 7 days-post injection and stained for T regulatory markers and EGFP fluorescence. The frequency of EGFP positive cells in the oligomer treated cohort was divided by the frequency of EGFP positive cells in saline treated mice to generate the fold increase in EGFP over vehicle. Results are presented in
The various embodiments described above can be combined to provide further embodiments. All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet, including but not limited to U.S. Provisional Patent Application No. 62/171,102 filed on Jun. 4, 2015, are incorporated herein by reference, in their entirety. Aspects of the embodiments can be modified, if necessary to employ concepts of the various patents, applications and publications to provide yet further embodiments.
These and other changes can be made to the embodiments in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.
Claims
1. A method for treatment of a lymphocyte-related disease or condition, the method comprising administering an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3′-end of one morpholino ring structure to a 5′-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has the following structure (I):
- or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein: R1 is guanidinyl, alkylguanidinyl or alkylaminyl; L1 is absent or present, and when present is selected from alkylene, aminoalkylene, oxyalkylene and thioalkylene; X is, at each occurrence, independently S or O; Y is, at each occurrence, independently —O— or —NH—; and Z is an optionally substituted 5, 6 or 7-membered heterocyclic ring.
2. The method of claim 1, wherein the morpholino ring structures have the following structure (i):
- wherein B is, at each occurrence, independently a base-pairing moiety.
3. The method of any one of claims 1-2, wherein Z is an optionally substituted 5 or 6-membered heterocyclic ring.
4. The method of claim 3, wherein Z is pyrrolidinyl, or piperidinyl.
5. The method of claim 4, wherein Z is piperidinyl.
6. The method of claim 4, wherein Z has one of the following structures:
7. The method of claim 6, wherein Z has the following structure:
8. The method of claim 7, wherein Z has the following structure:
9. The method of any one of claims 1-8, wherein R1 is guanidinyl.
10. The method of any one of claims 1-8, wherein R1 is alkylguanidinyl.
11. The method of claim 10, wherein alkylguanidinyl has the following structure:
- wherein R′ is C1-C6alkyl.
12. The method of claim 11, wherein R′ is methyl.
13. The method of any one of claims 1-8, wherein R1 is alkylaminyl.
14. The method of claim 13, wherein alkylaminyl is —NHR″, where R″ is C1-C6alkyl.
15. The method of claim 14, wherein R″ is methyl.
16. The method of any one of claim 1-15, wherein L1 is absent.
17. The method of any one of claims 1-16, wherein X is O.
18. The method of any one of claims 1-17, wherein Y is —O—.
19. The method of any one of claims 1-13, wherein at least one of the intersubunit linkages has the following structure (II):
- or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein: R2 and R3 are each independently H or C1-C6alkyl, X′ is S or O; and Y′ is —O— or —NH—.
20. The method of claim 19, wherein R2 and R3 are each methyl.
21. The method of claim 19 or 20 wherein X′ is O.
22. The method of any one of claims 19-21, wherein Y′ is —O—.
23. The method of claim 1, wherein at least one of the intersubunit linkages has the following structure:
24. The method of claim 1, wherein at least one of the intersubunit linkages has the following structure:
25. The method of claim 1, wherein at least one of the intersubunit linkages has the following structure:
26. The method of any one of claims 1-25, wherein the lymphocyte-related disease or condition is a T-cell-related disease or condition.
27. The method of claim 26, wherein the T-cell is an activated T-cell.
28. The method of claim 26, wherein the T-cell is a CD4 or CD8 cell.
29. The method of any one of claims 1-28, wherein the disease or condition is cancer or an autoimmune disease or condition.
30. A method for treatment of a T-cell related disease or condition, the method comprising contacting activated T-cells with an oligomer comprising a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3′-end of one morpholino ring structure to a 5′-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has the following structure (I):
- or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein: R1 is guanidinyl, alkylguanidinyl or alkylaminyl; L1 is absent or present, and when present is selected from alkylene, aminoalkylene, oxyalkylene, oxoalkylene and thioalkylene; X is, at each occurrence, independently S or O; Y is, at each occurrence, independently —O— or —NH—; and Z is an optionally substituted 5, 6 or 7-membered heterocyclic ring.
31. Use of an oligomer comprising a backbone having a sequence of morpholino ring structures joined by intersubunit linkages, the intersubunit linkages joining a 3′-end of one morpholino ring structure to a 5′-end of an adjacent morpholino ring structure, wherein each morpholino ring structure is bound to a base-pairing moiety, such that the oligomer can bind in a sequence-specific manner to a target nucleic acid, wherein at least one of the intersubunit linkages has the following structure (I):
- or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein: R1 is guanidinyl, alkylguanidinyl or alkylaminyl; L1 is absent or present, and when present is selected from alkylene, aminoalkylene, oxyalkylene, oxoalkylene and thioalkylene; X is, at each occurrence, independently S or O; Y is, at each occurrence, independently —O— or —NH—; and Z is an optionally substituted 5, 6 or 7-membered heterocyclic ring, for preparation of a pharmaceutical composition for treatment of a lymphocyte-related disease or condition.
Type: Application
Filed: Apr 30, 2021
Publication Date: Sep 16, 2021
Inventors: Dan V. Mourich (Cambridge, MA), Gunnar J. Hanson (Cambridge, MA), Frederick Joseph Schnell (Cambridge, MA), Johannes Christian Dworzak (Cambridge, MA)
Application Number: 17/245,456
